Evidence map›Paper›PMID 39789225›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2025

Lecanemab approval in EU: what should we be ready for?- the EANM perspective.

Igor Yakushev, Antoine Verger, Matthias Brendel, Diego Cecchin, Pablo Aguiar Fernandez, Francesco Fraioli, Timo Grimmer, Nelleke Tolboom, Tatjana Traub-Weidinger, Eric Guedj and 1 more

Abstract readEditorial
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Igor YakushevDepartment of Nuclear Medicine, School of Medicine, TUM University Hospital, Technical University of Munich, Klinikum rechts der Isar Ismaninger Str. 22, 81675, Munich, Germany. igor.yakushev@tum.de.
Antoine VergerDepartment of Nuclear Medicine and Nancyclotep Imaging Platform, CHRU Nancy, Université de Lorraine, Nancy, France.
Matthias BrendelDepartment of Nuclear Medicine, LMU Hospital, LMU Munich, Munich, Germany.
Diego CecchinDepartment of Medicine, Unit of Nuclear Medicine, University Hospital of Padova, Padova, Italy.
Pablo Aguiar FernandezCIMUS, Universidade Santiago de Compostela & Nuclear Medicine Department, Univ. Hospital IDIS, Santiago de Compostela, Spain.
Francesco FraioliInstitute of Nuclear Medicine, University College London, London, UK.
Timo GrimmerDepartment of Psychiatry and Psychotherapy, School of Medicine, TUM University Hospital, Technical University of Munich, Munich, Germany.
Nelleke TolboomDepartment of Radiology and Nuclear Medicine, University Medical Centre Utrecht, Utrecht, The Netherlands.
Tatjana Traub-WeidingerDepartment of Diagnostic and Therapeutic Nuclear Medicine, Clinic Donaustadt, Vienna Health Care Group, Vienna, Austria.
Eric GuedjDépartement de Médecine Nucléaire, Aix Marseille Univ, APHM, CNRS, Centrale Marseille, Institut Fresnel, Hôpital de La Timone, CERIMED, Marseille, France.
Donatienne Van WeehaegheDepartment of Radiology and Nuclear Medicine, Ghent University Hospital, Ghent, Belgium.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID39789225
PMCPMC11928400

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.